Immediate Breast Reconstruction Does Not Have a Clinically Significant Impact on Adjuvant Treatment Delay and Subsequent Survival Outcomes
- Author:
Seung Ho BAEK
1
;
Soon June BAE
;
Chang Ik YOON
;
So Eun PARK
;
Chi Hwan CHA
;
Sung Gwe AHN
;
Young Seok KIM
;
Tai Suk ROH
;
Joon JEONG
Author Information
- Publication Type:Original Article
- Keywords: Breast implants; Breast neoplasm; Chemotherapy, adjuvant; Radiotherapy, adjuvant; Recurrence
- MeSH: Breast Implants; Breast Neoplasms; Breast; Chemotherapy, Adjuvant; Cohort Studies; Drug Therapy; Female; Follow-Up Studies; Humans; Mammaplasty; Mastectomy; Propensity Score; Radiotherapy, Adjuvant; Recurrence; Retrospective Studies
- From:Journal of Breast Cancer 2019;22(1):109-119
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The use of immediate breast reconstruction (IBR) has been debated because it may be a causative factor in adjuvant treatment delay and may subsequently increase the probability of recurrence. We investigated whether IBR was related to adjuvant treatment delay and survival outcomes. METHODS: We retrospectively analyzed the duration from operation to adjuvant treatment administration and survival outcomes according to IBR status among patients with breast cancer who underwent mastectomy followed by adjuvant chemotherapy from January 2005 to December 2014. Propensity score matching was performed to balance the clinicopathologic baseline characteristics between patients who did and did not undergo IBR. RESULTS: Of 646 patients, 107 (16.6%) underwent IBR, and the median follow-up was 72 months. The median duration from surgery to adjuvant chemotherapy was significantly longer in patients who underwent IBR than in those who did not (14 vs. 12 days, respectively, p = 0.008). Based on propensity score matching, patients who underwent IBR received adjuvant therapy 3 days later than those who did not (14 vs. 11 days, respectively, p = 0.044). The duration from surgery to post-mastectomy radiation therapy (PMRT) did not significantly differ between the 2 groups. Local recurrence-free survival, regional recurrence-free survival, systemic recurrence-free survival, and overall survival were also not significantly different between the 2 groups (p = 0.427, p = 0.445, p = 0.269, and p = 0.250, respectively). In the case-matched cohort, survival outcomes did not change. CONCLUSION: IBR was associated with a modest increase in the duration from surgery to chemotherapy that was statistically but not clinically significant. Moreover, IBR had no influence on PMRT delay or survival outcomes, suggesting that it is an acceptable option for patients with non-metastatic breast cancer undergoing mastectomy.
